LC
CTXR icon

Luminist Capital’s Citius Pharmaceuticals CTXR Stock Holding History

Luminist Capital’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-435
Closed -$338 – 132
2025
Q4 		$338 Hold
435
– – ﹤0.01% 262
2025
Q3 		$596 Hold
435
– – ﹤0.01% 308
2025
Q2 		$827 Hold
435
– – ﹤0.01% 296
2025
Q1 		$522 Buy
435
+95
+28% +$227 ﹤0.01% 231
2024
Q4 		$1.36K Buy
+340
New +$2.29K ﹤0.01% 206

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Luminist Capital's CTXR Position: Q1 2026 in Review

Luminist Capital sold out of Citius Pharmaceuticals (CTXR) in Q1 2026, closing a stake of 435 shares — an estimated $338 sold.

Luminist Capital first reported a position in CTXR in Q4 2024 and held it in 5 quarters. The position peaked at $1.36K in Q4 2024. 38 funds tracked by Wall St. Rank hold CTXR as of Q1 2026.

  • Luminist Capital reported no remaining Citius Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Luminist Capital sold 435 Citius Pharmaceuticals shares in Q1 2026, an estimated $338.
  • Luminist Capital first reported a position in Citius Pharmaceuticals in Q4 2024 and held it in 5 quarters.
  • Luminist Capital's Citius Pharmaceuticals position peaked at $1.36K in Q4 2024.
  • 38 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2026.

Based on Luminist Capital's 13F filing for Q1 2026, filed 24 Apr 2026.